





The PELICAN (Prematurity's Effect on the Lungs In Children and Adults Network) ERS Clinical Research Collaboration: understanding the impact of preterm birth on lung health throughout life

Shannon J. Simpson 1,2 and Jenny Hallberg 3,4 on behalf of the PELICAN Clinical Research Collaboration 5

Affiliations: ¹Children's Lung Health, Wal-yan Respiratory Research Centre, Telethon Kids Institute, Perth, Australia. ²School of Allied Health, Curtin University, Perth, Australia. ³Dept of Clinical Sciences and Education, Karolinska Institutet, Stockholm, Sweden. ⁴Lung and Allergy Unit, Sachs' Children and Youth Hospital, Stockholm, Sweden. ⁵A list of members of the PELICAN Scientific Steering Committee can be found in the acknowledgements section.

Correspondence: Shannon J. Simpson, Wal-yan Respiratory Research Centre, Telethon Kids Institute, PO Box 855 West Perth, Australia. E-mail: shannon.simpson@telethonkids.org.au

@ERSpublications

Infants surviving preterm birth have persistent and potentially progressive respiratory health issues throughout life. PELICAN has been launched as an ERS Clinical Research Collaboration to understand the pulmonary consequences of surviving preterm birth. https://bit.ly/3q3DiHn

Cite this article as: Simpson SJ, Hallberg J. The PELICAN (Prematurity's Effect on the Lungs In Children and Adults Network) ERS Clinical Research Collaboration: understanding the impact of preterm birth on lung health throughout life. *Eur Respir J* 2021; 57: 2004387 [https://doi.org/10.1183/13993003.04387-2020].

This single-page version can be shared freely online.

An estimated 15 million babies (~11%) are born preterm each year (before 37 weeks of gestation), the rates of which are increasing worldwide [1]. Enhanced perinatal care, including antenatal corticosteroids, postnatal surfactant and improved respiratory management, have markedly improved survival outcomes since the 1990s, particularly for babies born very preterm (<32 weeks gestation) [1]. However, long-term pulmonary sequelae are frequent in preterm survivors and ongoing clinical management is often required. Development and severity of bronchopulmonary dysplasia (BPD), a chronic lung condition diagnosed during the neonatal period [2], is a key determinant of long-term adverse outcomes of prematurity.